Recorded Symposium Workshop: State of the Art Therapeutic Treatments for IBS Patients: Understanding the Role of the Gastroenterologist, Dietitian, and GI Psychologist
Gastrointestinal disorders are on the rise, with up to one in five Americans impacted by irritable bowel syndrome (IBS) alone. About two-thirds of those with IBS have perceived food as a trigger to their digestive distress. Emerging science in the field of food intolerance has provided insights into how food can contribute to the onset of symptoms of IBS, including the role of FODMAPs, histamine, and even table sugar, or sucrose.
Dietitians interested in working with patients with digestive challenges will benefit from this workshop as they begin to understand the wide range of holistic therapeutic treatments. Ranging from diet to gut-brain therapies, and including gut-directed hypnosis, cognitive behavioral therapy and more, the possibilities are extensive. Dr. William Chey, Dr. Megan Riehl, and Kate Scarlata, MPH, RDN make up a multi-disciplinary team, and join together in this session to teach dietitians about the specifics of their role, as well as the roles of other team members, in managing the patient’s care plan. Understanding the role of each team member is paramount to continuity of care and successful patient outcomes.
After attending this session, nutrition professionals should be able to:
- Detail the state of the evidence for food intolerance and its role in IBS symptom induction.
- Describe therapeutic behavioral therapies for IBS patients.
- Explain the three phases of the low FODMAP diet.
William D. Chey, MD, AGAF, FACG, FACP, received his bachelor’s degree from the University of Pennsylvania and medical degree and training in internal medicine at Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained as faculty at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He was awarded a joint appointment in the Department of Nutrition Sciences in 2015.
Dr. Chey’s research interests focus on the diagnosis and treatment of functional bowel disorders, acid-related disorders, and H. pylori infection. He is a medical innovator and holds 4 patents. He co-founded “My Total Health” (https://mygihealth.io/), a company developing novel health information technology solutions for persons with GI problems.
Dr. Chey has authored more than 300 manuscripts, reviews, chapters, and books. He served as co-editor-in-chief of the American Journal of Gastroenterology (2010-2015), founding co-editor of Clinical & Translational Gastroenterology (2011-2014). He led the ACG H. pylori practice guideline published in the American Journal of Gastroenterology in 2017. He served on the Editorial Board for the Rome IV criteria for the functional GI disorders published in 2016. He is a member of the ACG IBS Task Force responsible for the updated evidence-based monograph which will be published in 2018. He is working with the ACG, AGA and CAG on 3 additional clinical practice guidelines.
Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, and Council of the American Neurogastroenterology & Motility Society. He is Scientific Advisor for the International Foundation of Functional GI Disorders. He has been elected to “Best Doctors” since 2001, “America’s Top Doctors” since 2009, and repeatedly named as one of the Top Gastroenterologists in Detroit. He has received the Dean’s Outstanding Clinician Award and the Dean’s Award for Innovation & Commercialization at the University of Michigan and the Distinguished Clinician Award from the American Gastroenterological Association. He is past President of the Clinical Excellence Society in the Department of Medicine at Michigan Medicine.
The presenter has the following relevant disclosures to report regarding this program: Research Support: Biomerica, Ironwood, Commonwealth Diagnostics, QOL Medical, Salix Pharmaceuticals, Urovant, Takeda, Zespri. Consultant: Allergan, Biomerica, IM Health, Ironwood, QOL Medical, Salix/Valent, Phathom, Redhill, Ritter. He has certified that no conflict of interest exists for this program. View our disclosure policy.
Megan Riehl, PsyD, is a GI psychologist who specializes in psychogastroenterology and anxiety related-disorders. She is the Clinical Director of the GI behavioral health program at the University of Michigan offering comprehensive treatment options for patients in the GI department. Working from a collaborative perspective, treatment can be focused on improving one's quality of life, decreasing the frequency and intensity of medical symptoms, establishing healthy stress management tools and improving coping skills. Her approach relies on principles of cognitive-behavioral therapy to design unique and flexible treatment plans tailored to the individual.
Dr. Riehl’s clinical research focuses on the delivery of GI behavioral health treatment for patients with disorders of the brain-gut and IBD. Dr. Riehl is the co-chair for the ROME Foundation Psychogastroenterology Education and Training committee, participates on two national committees pertaining to the psychosocial aspects of IBD with the Crohn’s and Colitis Foundation and sits on the Membership and Mentorship committee with the American Neurogastroenterology and Motility Society.
The presenter has the following relevant disclosures to report regarding this program: Consultant: Gastro Girl, Inc. She has certified that no conflict of interest exists for this program. View our disclosure policy.
Kate Scarlata, MPH, RDN, LDN is a Boston-based dietitian with 30 years of experience. Kate’s expertise is in gastrointestinal disorders and food intolerance, with a particular focus on the application of the low FODMAP diet for functional gut disorders. She was awarded the Outstanding Massachusetts Dietitian Award and recognized as Boston’s Best Dietitian by Boston Magazine. Kate is the author of numerous books and articles on digestive health topics including the New York Times Best Seller, “The 21 Day Tummy Diet.” Her latest book is “The Low FODMAP Diet Step by Step.” Kate completed her postgraduate training at Brigham and Women’s Hospital, a Harvard Medical School teaching affiliate.
The presenter has the following relevant disclosures to report regarding this program: Equity: Fody food co., Epicured. Honorarium/Consultant: A2 Milk Company, Enjoy Life Foods, Green Valley Creamery, Monash University, Salix Pharmaceuticals. Published books and online low FODMAP educational handouts. She has certified that no conflict of interest exists for this program. View our disclosure policy.
- 3.50 CDR